Caputron Medical has announced the FDA approval of its mindGear headset, a device designed to treat depression, insomnia and anxiety without the use of drugs.
The device, which uses neuromodulation, has undergone therapy optimization and clinical testing at world leading medical centers, including Harvard Medical School, over the past 5 years serves as a solution for those who have not experienced relief after pharmaceutical treatment.
Jennifer Higgins, Vice President for U.S. Sales said in a statement: “mindGear represents a major advance in the wearable tech and digital health space. Portable, personal, and customizable, mindGear is both a consumer and medical neuromodulation device.”
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The prescribed device is battery powered and connects to the head through hydroPod electrodes. The therapy is described as painless and sessions last approximately 30 minutes. It is available at mindGear.CaputronMedical.com
Caputron CEO Robin Azzam said in a company statement: “Neuromodulation, also called electroceuticals, is the fastest growing area in the treatment of neurological and psychiatric disorders. mindGear further establishes Caputron Medical as a leader in the personalized therapy space with a hand-held and personalized device.”
Photo: Screenshot via Caputron